Back

Daniel F. Sahm, PhD

VP Global Microbiology Services & Chief Scientific Officer
IHMA

Disclosure(s): No financial relationships to disclose

Poster(s):

1670 - Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1671 - Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1672 - Antimicrobial Activity of Cefepime-Taniborbactam and Comparators Against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1673 - In vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1674 - Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1707 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Adult Patients, ATLAS Global Surveillance Program 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1708 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Pediatric Patients, ATLAS Global Surveillance Program 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1709 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America, ATLAS Global Surveillance Program 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1710 - In Vitro Activity of Cefepime-Taniborbactam and Comparators Against a Global Collection of Carbapenem-Resistant Enterobacterales and Carbapenem-Resistant Pseudomonas aeruginosa With and Without Carbapenemases
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1717 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1718 - In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1719 - In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1720 - In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Urinary Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET